<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03795558</url>
  </required_header>
  <id_info>
    <org_study_id>Etelcalcetide-T50-CKD5D</org_study_id>
    <nct_id>NCT03795558</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients</brief_title>
  <official_title>A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prim. Priv. Doz. Dr. Daniel Cejka</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Elisabethinen Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, prospective, dose-escalation, pilot study in 15 end-stage renal
      disease patients on chronic hemodialysis with secondary hyperparathyroidism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifteen prevalent and stable hemodialysis patients with secondary hyperparathyroidism
      eligible for treatment with calcium receptor sensitizers according to current KDIGO will be
      included.

      Study phases will begin and end on the day of the first hemodialysis session of the week.

      The run-in phase will last 4 weeks. No calcimimetics will be prescribed during the run-in
      phase.

      The treatment phase starts with a dose of etelcalcetide is 2.5mg thrice weekly. Etelcalcetide
      dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose
      of 15mg thrice weekly.

      The wash-out Phase starts after completion of the 15mg thrice-weekly phase or in case a
      pre-specified safety endpoint is reached, etelcalcetide will be discontinued and patients
      will be followed for additional 8 weeks to study any potential reversibility of PTH lowering
      on T50 results.

      For the individual patient, the study duration will be 9 months
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a single-center, prospective, dose-escalation, pilot study. Starting dose 2.5 mg thrice weekly dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T50-Laboratory Test for measuring calcification</measure>
    <time_frame>32 weeks</time_frame>
    <description>The changes in T50 values between the different study phases will be evaluated as the primary outcome.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Etelcalcetide 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etelcalcetide 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etelcalcetide 7,5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etelcalcetide 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etelcalcetide 12,5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etelcalcetide 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etelcalcetide</intervention_name>
    <description>Up-Titration</description>
    <arm_group_label>Etelcalcetide 10 mg</arm_group_label>
    <arm_group_label>Etelcalcetide 12,5 mg</arm_group_label>
    <arm_group_label>Etelcalcetide 15 mg</arm_group_label>
    <arm_group_label>Etelcalcetide 2.5 mg</arm_group_label>
    <arm_group_label>Etelcalcetide 5 mg</arm_group_label>
    <arm_group_label>Etelcalcetide 7,5 mg</arm_group_label>
    <other_name>Parsabiv</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prevalent patients (≥ 3 months on dialysis) treated with thrice weekly hemodialysis
             (HD) or hemodiafiltration (HDF)

          -  Secondary hyperparathyroidism defined as PTH levels &gt; 9x ULN according to current
             KDIGO guidelines if therapy-naïve, or patients already treated with calcium receptor
             sensitizers with PTH &gt; 2x ULN

          -  Albumin corrected calcium ≥ 2,08 mmol/l

          -  Calcium concentrations of dialysate stable for at least 2 weeks prior to screening

        Exclusion Criteria:

          -  Currently receiving treatment in another investigational device or drug study or
             participation in non-interventional studies

          -  Current treatment with etelcalcetide (Parsabiv©) or treatment with etelcalcetide
             within 3 months prior to study inclusion

          -  Patient has known sensitivity to any of the products or components of Parsabiv©

          -  Patient has received a parathyroidectomy

          -  Parathyroidectomy planned or expected during the study period

          -  Elective kidney transplant scheduled during the study period

          -  Therapy with bisphosphonates within the past 12 months

          -  Therapy with denosumab within the past 6 months

          -  Antacids containing aluminum, calcium, magnesium or bicarbonate

          -  Patient has a history of symptomatic ventricular arrhythmias or Torsades de Pointes

          -  Patient has a history of myocardial infarction, coronary angioplasty, or coronary
             arterial bypass grafting within the past 6 months prior to screening.

          -  Pregnant or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Cejka, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Nephrology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Dumfarth, PMSc</last_name>
    <phone>00437327676</phone>
    <phone_ext>4302</phone_ext>
    <email>alexandra.dumfarth@ordensklinikum.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Cejka, MD</last_name>
    <phone>00437327676</phone>
    <phone_ext>4300</phone_ext>
    <email>daniel.cejka@ordensklinikum.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH Elisabethinen</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Dumfarth, PMSc</last_name>
      <phone>004373276764302</phone>
      <email>alexandra.dumfarth@ordensklinikum.at</email>
    </contact>
    <contact_backup>
      <last_name>Angela Kapsammer</last_name>
      <phone>004373276764303</phone>
      <email>angela.kapsammer@ordensklinikum.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2019</study_first_posted>
  <last_update_submitted>July 19, 2019</last_update_submitted>
  <last_update_submitted_qc>July 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Elisabethinen Hospital</investigator_affiliation>
    <investigator_full_name>Prim. Priv. Doz. Dr. Daniel Cejka</investigator_full_name>
    <investigator_title>Head of Nephrology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

